Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects.

Histone deacetylases (HDACs) catalyze the hydrolysis of acetyl-l-lysine side chains in histones and non-histones, which are key to epigenetic regulation in humans. Targeting HDACs has emerged as a promising strategy for treating various types of cancer, including myeloma and hematologic malignancies. At present, numerous small molecule inhibitors targeting HDACs are actively being investigated in clinical trials. Despite their potential efficacy in cancer treatment, HDAC inhibitors suffer from multi-directional selectivity and preclinical resistance issues. Hence, developing novel inhibitors based on cutting-edge medicinal chemistry techniques is essential to overcome these limitations and improve clinical outcomes. This manuscript presents an extensive overview of the properties and biological functions of HDACs in cancer, provides an overview of the current state of development and limitations of clinical HDAC inhibitors, and analyzes a range of innovative medicinal chemistry techniques that are applied. These techniques include selective inhibitors, dual-target inhibitors, proteolysis targeting chimeras, and protein-protein interaction inhibitors.Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Citation

Jinxiao Ru, Yuxi Wang, Zijia Li, Jiaxing Wang, Changyu Ren, Jifa Zhang. Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects. European journal of medicinal chemistry. 2023 Sep 09;261:115800115800

PMID: 37708798

search → result